CMS finalizes Medicare coverage policy for Alzheimer’s drug
The Centers for Medicare & Medicaid Services yesterday finalized a decision to cover only for Medicare beneficiaries enrolled in qualifying clinical trials monoclonal antibodies that target amyloid to treat Alzheimer’s disease when approved by the Food and Drug Administration. The FDA last year approved the first such Alzheimer’s treatment, Biogen’s Aduhelm (aducanumab), using its accelerated approval pathway.
Related News Articles
Headline
A KFF analysis released Jan. 28 found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase…
Headline
The Centers for Medicare & Medicaid Services Jan. 26 released proposed changes to Medicare Advantage plan capitation rates and Part D payment policies for…
Headline
The AHA Jan. 26 expressed support and provided its perspective on certain provisions within the Centers for Medicare & Medicaid Services’ proposed…
Headline
The AHA Jan. 20 made recommendations to Congress on modernizing the Medicare Access and CHIP Reauthorization Act. Among the proposals, the AHA recommended…
Headline
The comment period for the Centers for Medicare & Medicaid Services' proposed rule for policies governing the Medicare Advantage and Part D programs for…
Headline
The Medicare Payment Advisory Commission Jan. 15 voted to recommend that Congress update Medicare payment rates for hospital inpatient and outpatient services…